FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201847844> ?p ?o ?g. }

• W3201847844 endingPage "45" @default.
• W3201847844 startingPage "38" @default.
• W3201847844 abstract "Oral anticoagulants (OACs), including warfarin and newer direct-acting OACs (DOACs), have been used for decades to prevent thromboembolic diseases. A drug utilization study was performed to determine the prescribing patterns of OACs.Data were extracted from the Cooperation Project of Hospital Prescription Analysis in China. A total of 455,490 prescription records from 43 tertiary hospitals in five cities of China (Beijing, Shanghai, Guangzhou, Hangzhou and Chengdu) were selected for inclusion. Quarterly trends of defined daily doses (DDDs) and defined daily dose cost (DDDC) from 1 January 2015 to 31 December 2019 were calculated.Warfarin was the most widely used OAC with DDDs between 189,982 and 176,323 from the first quarter (Q1) of 2015 to the fourth quarter (Q4) of 2019, whereas the use of DOACs increased rapidly during this period. DDDs of rivaroxaban increased from 5409 in Q1 of 2015 to 125,800 in Q4 of 2019, whereas the DDDC declined from 160.5 to 45.7. From Q1 of 2018, rivaroxaban became the most prescribed OAC, surpassing warfarin, in patients diagnosed with deep vein thrombosis. In addition, the DDDs of rivaroxaban exceeded those of warfarin in patients diagnosed with non-valvular atrial fibrillation since the second quarter (Q2) of 2019. DDDs in outpatients and inpatients increased by 80.6% and 71.4%, respectively, and the DDDC for outpatients in Q4 of 2019 was 6.7-fold higher than that in Q1 of 2015. Among patients of all ages, the DDDs in elderly patients increased from 36.8% in Q1 of 2015 to 59.4% in Q4 of 2019. Moreover, the departments of cardiology and cardiothoracic surgery prescribed the majority of the OACs.In this study, we describe OAC prescription patterns in China. DOACs, especially rivaroxaban, contribute to the continuous increase in the use of OACs. In the investigated population of China, outpatients and elderly patients were observed to be administered the highest proportion of DOACs." @default.
• W3201847844 created "2021-10-11" @default.
• W3201847844 creator A5009543413 @default.
• W3201847844 creator A5010479652 @default.
• W3201847844 creator A5023487841 @default.
• W3201847844 creator A5025226154 @default.
• W3201847844 creator A5027649946 @default.
• W3201847844 creator A5034654778 @default.
• W3201847844 creator A5072815126 @default.
• W3201847844 creator A5087469296 @default.
• W3201847844 date "2021-09-30" @default.
• W3201847844 modified "2023-09-23" @default.
• W3201847844 title "A drug utilization study of oral anticoagulants in five representative cities of China between 2015 and 2019" @default.
• W3201847844 cites W1597337165 @default.
• W3201847844 cites W1994783449 @default.
• W3201847844 cites W1997977417 @default.
• W3201847844 cites W2031872902 @default.
• W3201847844 cites W2043351648 @default.
• W3201847844 cites W2067883921 @default.
• W3201847844 cites W2097854437 @default.
• W3201847844 cites W2136489990 @default.
• W3201847844 cites W2162508946 @default.
• W3201847844 cites W2225937646 @default.
• W3201847844 cites W2275481599 @default.
• W3201847844 cites W2294236942 @default.
• W3201847844 cites W2318561249 @default.
• W3201847844 cites W2362016459 @default.
• W3201847844 cites W2547585100 @default.
• W3201847844 cites W2562101665 @default.
• W3201847844 cites W2582505536 @default.
• W3201847844 cites W2604738434 @default.
• W3201847844 cites W2739421744 @default.
• W3201847844 cites W2751630023 @default.
• W3201847844 cites W2769275060 @default.
• W3201847844 cites W2794584423 @default.
• W3201847844 cites W2801026438 @default.
• W3201847844 cites W2801590965 @default.
• W3201847844 cites W2805753864 @default.
• W3201847844 cites W2888676709 @default.
• W3201847844 cites W2902233584 @default.
• W3201847844 cites W2902418274 @default.
• W3201847844 cites W2909055118 @default.
• W3201847844 cites W2912772408 @default.
• W3201847844 cites W2921080115 @default.
• W3201847844 cites W2928924118 @default.
• W3201847844 cites W2963243813 @default.
• W3201847844 cites W2972019042 @default.
• W3201847844 cites W2979951648 @default.
• W3201847844 cites W2981488777 @default.
• W3201847844 cites W3011376634 @default.
• W3201847844 cites W3092849554 @default.
• W3201847844 cites W4211129082 @default.
• W3201847844 doi "https://doi.org/10.1111/jcpt.13538" @default.
• W3201847844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34592785" @default.
• W3201847844 hasPublicationYear "2021" @default.
• W3201847844 type Work @default.
• W3201847844 sameAs 3201847844 @default.
• W3201847844 citedByCount "2" @default.
• W3201847844 countsByYear W32018478442022 @default.
• W3201847844 countsByYear W32018478442023 @default.
• W3201847844 crossrefType "journal-article" @default.
• W3201847844 hasAuthorship W3201847844A5009543413 @default.
• W3201847844 hasAuthorship W3201847844A5010479652 @default.
• W3201847844 hasAuthorship W3201847844A5023487841 @default.
• W3201847844 hasAuthorship W3201847844A5025226154 @default.
• W3201847844 hasAuthorship W3201847844A5027649946 @default.
• W3201847844 hasAuthorship W3201847844A5034654778 @default.
• W3201847844 hasAuthorship W3201847844A5072815126 @default.
• W3201847844 hasAuthorship W3201847844A5087469296 @default.
• W3201847844 hasBestOaLocation W32018478441 @default.
• W3201847844 hasConcept C126322002 @default.
• W3201847844 hasConcept C17744445 @default.
• W3201847844 hasConcept C191935318 @default.
• W3201847844 hasConcept C194828623 @default.
• W3201847844 hasConcept C199539241 @default.
• W3201847844 hasConcept C2426938 @default.
• W3201847844 hasConcept C2776301958 @default.
• W3201847844 hasConcept C2776865356 @default.
• W3201847844 hasConcept C2778304055 @default.
• W3201847844 hasConcept C2778661090 @default.
• W3201847844 hasConcept C2779161974 @default.
• W3201847844 hasConcept C71924100 @default.
• W3201847844 hasConcept C98274493 @default.
• W3201847844 hasConceptScore W3201847844C126322002 @default.
• W3201847844 hasConceptScore W3201847844C17744445 @default.
• W3201847844 hasConceptScore W3201847844C191935318 @default.
• W3201847844 hasConceptScore W3201847844C194828623 @default.
• W3201847844 hasConceptScore W3201847844C199539241 @default.
• W3201847844 hasConceptScore W3201847844C2426938 @default.
• W3201847844 hasConceptScore W3201847844C2776301958 @default.
• W3201847844 hasConceptScore W3201847844C2776865356 @default.
• W3201847844 hasConceptScore W3201847844C2778304055 @default.
• W3201847844 hasConceptScore W3201847844C2778661090 @default.
• W3201847844 hasConceptScore W3201847844C2779161974 @default.
• W3201847844 hasConceptScore W3201847844C71924100 @default.
• W3201847844 hasConceptScore W3201847844C98274493 @default.
• W3201847844 hasIssue "1" @default.
• W3201847844 hasLocation W32018478441 @default.

• next